PCH
CYTK icon

Polar Capital Holdings’s Cytokinetics CYTK Stock Holding History

Polar Capital Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,000
Closed -$2.1M – 254
2025
Q4 		$2.1M Buy
+33,000
New +$2.05M 0.01% 250

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Polar Capital Holdings's CYTK Position: Q1 2026 in Review

Polar Capital Holdings reduced its Cytokinetics (CYTK) stake by 31% in Q1 2026, selling an estimated $48.4M and leaving 1,661,248 shares worth $109M. The position accounts for 0.39% of the portfolio, ranked #61.

Polar Capital Holdings first reported a position in CYTK in Q4 2020 and has held it in 22 quarters since. The position peaked at $154M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Polar Capital Holdings held 1,661,248 shares of Cytokinetics worth $109M as of Q1 2026.
  • Polar Capital Holdings sold 761,364 Cytokinetics shares in Q1 2026, an estimated $48.4M.
  • Cytokinetics made up 0.39% of Polar Capital Holdings's portfolio in Q1 2026, its #61 holding.
  • Polar Capital Holdings first reported a position in Cytokinetics in Q4 2020 and has held it in 22 quarters since.
  • Polar Capital Holdings's Cytokinetics position peaked at $154M in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.